List of Excipients in Branded Drug AUSTEDO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Neuroscience Inc	AUSTEDO	deutetrabenazine	68546-170	AMMONIA	2034-03-18
Teva Neuroscience Inc	AUSTEDO	deutetrabenazine	68546-170	BUTYL ALCOHOL	2034-03-18
Teva Neuroscience Inc	AUSTEDO	deutetrabenazine	68546-170	BUTYLATED HYDROXYANISOLE	2034-03-18

AUSTEDO Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

AUSTEDO’s excipient opportunity is concentrated in differentiated oral delivery, not simple ingredient substitution. Teva’s deutetrabenazine products use conventional tablet excipients, while the commercial value is protected primarily by the active pharmaceutical ingredient, dosage regimen, formulation performance, regulatory data, and market access. The strongest opportunities are lower-pill-burden products, swallowability improvements, sprinkle or liquid presentations, pediatric and geriatric delivery, and robust generic formulations that avoid infringing formulation or process claims.

What is AUSTEDO and which formulations are commercially relevant?

AUSTEDO contains deutetrabenazine, a deuterated form of tetrabenazine. It is approved for chorea associated with Huntington’s disease and for tardive dyskinesia in adults. AUSTEDO is marketed as immediate-release tablets and AUSTEDO XR as an extended-release tablet taken once daily.[1,2]

Product	Active ingredient	Route	Approved uses	Dosing profile	Commercial relevance
AUSTEDO tablets	Deutetrabenazine	Oral	Huntington’s disease chorea; tardive dyskinesia	Divided daily dosing, titrated by indication	Established product with high adherence burden
AUSTEDO XR	Deutetrabenazine	Oral	Huntington’s disease chorea; tardive dyskinesia	Once daily	Lower pill burden and stronger lifecycle position
Generic deutetrabenazine	Deutetrabenazine	Oral	Depends on ANDA approval	Bioequivalent to reference product	Price competition and formulation design opportunity
Potential 505(b)(2) product	Deutetrabenazine or related delivery form	Oral	New or modified presentation	Could support altered dosing or administration	Higher development burden but broader differentiation

AUSTEDO XR is commercially important because it converts a multiple-dose regimen into once-daily administration. That change reduces the immediate attractiveness of conventional excipient reformulation unless the new product solves a separate problem, such as inability to swallow tablets, administration in long-term-care settings, or dose titration complexity.

What excipients are used in AUSTEDO tablets and AUSTEDO XR?

AUSTEDO uses common oral solid-dose excipients, including lactose-based fillers, cellulose or starch-based diluents, disintegrants, glidants, lubricants, and film-coating materials. The precise excipient composition differs by dosage form and strength and should be taken from the current FDA-approved prescribing information and product-specific labeling.[1,2]

AUSTEDO immediate-release tablets

The immediate-release product uses a conventional compressed-tablet platform. Its excipient strategy supports:

• Adequate tablet hardness at low active-drug loading.
• Rapid disintegration and dissolution.
• Dose flexibility across multiple strengths.
• Film-coating color differentiation.
• Manufacturing at commercial scale using established equipment.

The likely commercial design constraints are not unusual excipient availability. They are content uniformity, dissolution matching, stability of the deuterated active ingredient, and bioequivalence across the approved strength range.

AUSTEDO XR tablets

The extended-release product requires a controlled-release matrix or equivalent release-controlling architecture. Its excipients must regulate drug diffusion, tablet hydration, erosion, or a combination of those mechanisms.

Potential functional excipient classes include:

Functional role	Relevant excipient classes	Strategic purpose
Matrix former	Hypromellose, hydroxypropyl cellulose, other hydrophilic polymers	Controls hydration and drug release
Diluent	Lactose, microcrystalline cellulose, mannitol	Adjusts tablet mass and compressibility
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Supports immediate-release performance where required
Lubricant	Magnesium stearate, sodium stearyl fumarate	Improves ejection and manufacturing throughput
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose, polyvinyl alcohol	Protects the tablet and enables identification
Opacifier and colorant	Titanium dioxide, iron oxides, approved colorants	Supports product identification and light protection

The commercial issue is that the XR formulation cannot be treated as a simple immediate-release tablet with a different coating. A generic or follow-on product must match the reference release profile across multiple time points and may require comparative pharmacokinetic studies under fed and fasted conditions.

Which excipient strategies can improve AUSTEDO products?

The most attractive strategies address administration barriers rather than replacing common excipients without a performance benefit.

1. Low-pill-burden and dose-flexible formulations

AUSTEDO XR already addresses once-daily use. Further opportunity exists in:

• Higher-strength tablets that reduce tablet count.
• Scored tablets where compatible with dose uniformity and release requirements.
• Multiparticulate capsules with flexible dose delivery.
• Unit-dose sachets or blister presentations for titration.

A higher-strength formulation must maintain content uniformity, acceptable tablet size, and dose flexibility. For an XR product, scoring or subdivision can create a material release-risk issue and would require direct evidence.

2. Sprinkle and feeding-tube presentations

AUSTEDO tablets are not interchangeable with a sprinkle formulation. A new product could use coated multiparticulates in a capsule or sachet. The formulation would need to preserve:

• Extended-release characteristics.
• Particle-size uniformity.
• Protection from chewing.
• Compatibility with soft foods.
• Stability after opening.
• Administration through applicable enteral feeding tubes.

This is a credible 505(b)(2) opportunity because the administration route remains oral but the dosage form and handling instructions differ. The regulatory burden would be higher than for an ordinary ANDA, particularly if the product changes pharmacokinetics or requires new clinical-use instructions.

3. Orally disintegrating or rapidly dispersible dosage forms

An orally disintegrating tablet could target patients with dysphagia, neurodegenerative disease, or dependence on caregivers. Immediate-release deutetrabenazine is more suitable for this approach than XR because extended release is difficult to preserve in a rapidly disintegrating tablet.

Key excipient requirements include:

• High-porosity filler systems.
• Direct-compression functionality.
• Taste masking.
• Low friability.
• Rapid disintegration.
• Low moisture sensitivity.

Deutetrabenazine’s dose and pharmacologic activity make taste masking important. Sweeteners and flavors alone may not be adequate. Ion-exchange resins, polymer coatings, lipid barriers, or complexation approaches could be evaluated, but each may affect dissolution and absorption.

4. Oral liquid or concentrated suspension

A liquid formulation would address patients unable to swallow tablets and could support caregiver administration. The main technical issues are:

• Low aqueous solubility or suspension stability.
• Dose uniformity after shaking.
• Chemical stability.
• Microbial control.
• Taste masking.
• Container-closure compatibility.
• Measuring-device accuracy.

A liquid product could use a suspension rather than a true solution if solubilization requires excessive cosolvent or surfactant levels. Commercial value would depend on whether the target population is large enough to support specialized manufacturing, packaging, and distribution costs.

5. Pediatric and geriatric delivery

Huntington’s disease is primarily an adult indication, while tardive dyskinesia is also concentrated in adults. The clearest geriatric opportunity is a formulation that supports dysphagia, caregiver administration, and medication reconciliation in institutional settings.

Potential products include:

• Small-volume oral suspensions.
• Multiparticulate sprinkle capsules.
• Unit-dose oral powders.
• Ready-to-administer oral syringes.
• Low-dose titration presentations.

These products could support new clinical-use instructions and potentially receive regulatory protection tied to new formulation or clinical data.

How strong is the AUSTEDO excipient patent estate?

The commercial strength of an excipient strategy depends on claim scope, not on the number of excipients listed in the formulation. Conventional excipients generally provide limited standalone protection because lactose, microcrystalline cellulose, magnesium stearate, hypromellose, and common disintegrants are widely used.

A stronger formulation patent typically claims one or more of the following:

1. A defined release profile.
2. A specified polymer-to-drug ratio.
3. A narrow dissolution window.
4. A combination of deutetrabenazine and selected excipients.
5. A manufacturing process that produces a controlled microstructure.
6. Stability under defined temperature and humidity conditions.
7. A multiparticulate or coated-particle architecture.
8. A specific pharmacokinetic profile.
9. A method of treating a protected patient population with the dosage form.

The central distinction is between a composition claim and a performance claim. A claim that merely lists common excipients is easier to design around. A claim tied to dissolution, pharmacokinetics, particle coating, or process conditions can impose a greater barrier if the reference product depends on those characteristics.

Key patent risks for alternative formulations

Patent issue	Risk to a competing product	Design-around potential
Deutetrabenazine composition patents	High	Low to moderate
XR release-profile claims	High	Moderate
Specific polymer matrix claims	Moderate to high	Moderate to high
Common excipient combinations	Moderate	High
Manufacturing-process claims	Moderate	Moderate
Sprinkle or liquid formulation claims	Depends on filing date and scope	Often available through alternative architecture
Method-of-use claims	Depends on indication and labeling	Moderate through label strategy

Public patent records identify active-ingredient, formulation, and use-related rights associated with deutetrabenazine products. A commercial assessment must separate Orange Book-listed patents from non-listed patents, pending applications, foreign rights, and patents that may be asserted under the Hatch-Waxman framework.[3,4]

When does AUSTEDO lose exclusivity?

AUSTEDO’s market protection has several layers:

Protection layer	Relevance to AUSTEDO
New chemical entity exclusivity	Deutetrabenazine is a deuterated derivative of tetrabenazine, so the applicable exclusivity analysis is not equivalent to a first-in-class NCE with no related approved product
Orphan-drug exclusivity	The Huntington’s disease chorea indication received orphan-drug treatment; the seven-year period from the original approval was tied to the indication and approval date
Three-year clinical-investigation exclusivity	May attach to qualifying supplemental approvals, but does not block all ANDA activity
Orange Book patents	Can delay approval or create Paragraph IV litigation exposure
Pediatric exclusivity	Applies only if FDA granted the relevant six-month extension
Regulatory exclusivity for XR	Depends on the approval basis and qualifying clinical investigations

FDA approved AUSTEDO in April 2017 for chorea associated with Huntington’s disease and later approved it for tardive dyskinesia in August 2017.[5,6] FDA approved AUSTEDO XR in 2023.[2]

The practical generic-entry date cannot be determined from the approval date alone. It depends on listed patent expiration dates, pediatric extensions, court outcomes, settlement terms, regulatory exclusivity, and the first applicant’s status. A Paragraph IV certification can trigger litigation and a 30-month stay under the conditions established by the Hatch-Waxman Act.[7]

What is the Orange Book status of AUSTEDO?

AUSTEDO and AUSTEDO XR should be evaluated separately in the FDA Orange Book because the products have different dosage forms, release characteristics, and approval histories.[3]

The relevant Orange Book questions are:

• Which patents are listed against AUSTEDO tablets?
• Which patents are listed against AUSTEDO XR?
• Are the patents composition, formulation, method-of-use, or drug-delivery patents?
• What are the listed expiration dates?
• Is pediatric exclusivity attached?
• Have applicants submitted Paragraph IV certifications?
• Has Teva filed timely infringement actions?
• Has FDA recognized any first-filer eligibility or 180-day exclusivity?

Orange Book listings are important for ANDA timing but do not capture the entire freedom-to-operate position. Non-listed manufacturing, polymorph, intermediate, process, packaging, and foreign patents can still affect commercial launch.

Which companies are challenging AUSTEDO?

A generic challenge would normally be made through an ANDA with Paragraph IV certification against listed patents. The public record should be reviewed by product and dosage form because an applicant may challenge AUSTEDO tablets without challenging AUSTEDO XR, or may target only selected strengths.

The most commercially relevant challenger categories are:

• Large generic manufacturers with CNS portfolios.
• Specialty generics companies willing to develop modified-release products.
• Contract development manufacturers with controlled-release capability.
• 505(b)(2) developers pursuing alternative administration.

The absence of a publicly confirmed settlement or final judgment should not be treated as evidence that generic risk is low. The key variables are the number of ANDAs, certification dates, asserted patent claims, district-court outcomes, and any agreed launch date.

What formulation patents could protect new AUSTEDO products?

A new AUSTEDO-related product would have the strongest IP position if it combines a clinically meaningful delivery advantage with measurable formulation differences.

Potential protected formulation categories

• Once-daily matrix tablets.
• Deutetrabenazine multiparticulates with controlled-release coatings.
• Sprinkle capsules that maintain extended release after administration with food.
• Taste-masked oral suspensions.
• Low-dose titration kits.
• Moisture-stable ODTs.
• Enteral-tube-compatible formulations.
• Specific impurity-control systems.
• Manufacturing processes that limit degradation or improve uniformity.
• Packaging systems that protect against humidity or light.

A patent application should avoid claiming only a broad list of routine excipients. Narrower claims linked to dissolution, stability, particle morphology, coating thickness, or clinical pharmacokinetics are more likely to provide enforceable differentiation.

How does AUSTEDO compare with INGREZZA?

AUSTEDO competes directly with INGREZZA, which contains valbenazine and is marketed by Neurocrine Biosciences for tardive dyskinesia and Huntington’s disease chorea.[8]

Attribute	AUSTEDO	INGREZZA
Active ingredient	Deutetrabenazine	Valbenazine
Initial FDA approval	2017	2017
Tardive dyskinesia	Approved	Approved
Huntington’s disease chorea	Approved	Approved
Immediate-release option	Yes	No conventional equivalent to AUSTEDO tablets
Extended-release option	AUSTEDO XR	Once-daily INGREZZA capsules
Excipient opportunity	XR, sprinkle, liquid, ODT, dose-flexible formats	Capsule, sprinkle, liquid, or alternate delivery opportunities
Competitive issue	Titration and pill burden	Once-daily simplicity and brand persistence

AUSTEDO’s immediate-release and XR portfolio gives Teva multiple dosage-form positions. INGREZZA’s once-daily profile creates pressure for AUSTEDO to defend adherence, tolerability, and ease of administration. For an excipient developer, both products offer opportunities in dysphagia, caregiver administration, and alternate oral delivery.

What commercial opportunities exist for excipient suppliers and formulation developers?

Excipient suppliers

The largest opportunity is not supplying commodity lactose or magnesium stearate. It is supplying functional excipients with documented performance in controlled-release or orally disintegrating systems.

Commercially relevant offerings include:

• Direct-compression excipients that reduce manufacturing variability.
• Low-moisture excipients for stability-sensitive formulations.
• Co-processed excipients for high-dose tablet compression.
• Taste-masking polymers.
• Controlled-release matrix polymers.
• Excipient systems qualified for pediatric or geriatric use.
• Ready-to-use granulation platforms.
• Film-coating systems with improved color consistency and moisture protection.

CDMOs and generic developers

AUSTEDO creates opportunities for companies with:

• Modified-release development capability.
• In vitro-in vivo correlation expertise.
• Multiparticulate coating equipment.
• High-containment oral-solid manufacturing.
• Analytical methods for low-level impurities.
• Regulatory experience with ANDA and 505(b)(2) submissions.
• Commercial packaging for titration and adherence programs.

The most defensible commercial strategy is a differentiated product that combines a formulation advantage with a regulatory pathway. A conventional tablet containing the same active ingredient and similar excipients will face price competition and patent risk without a clear market-access benefit.

What manufacturing and IP barriers affect AUSTEDO competition?

The principal barriers are technical and legal.

Manufacturing barriers

Controlled-release products require tight control over:

• Granule particle size.
• Polymer distribution.
• Compression force.
• Tablet porosity.
• Coating thickness.
• Dissolution under multiple media conditions.
• Scale-up behavior.
• Stability after packaging.

A product can pass a single dissolution test and still fail comparative performance because modified-release systems are sensitive to manufacturing changes.

IP barriers

The relevant IP review should cover:

• Active ingredient patents.
• Salt, crystal, and polymorph patents.
• Formulation patents.
• Controlled-release patents.
• Process patents.
• Intermediate and impurity-control patents.
• Packaging and stability patents.
• Method-of-use patents.
• Foreign patents in target launch markets.

U.S. patent clearance does not establish freedom to operate in Europe, Canada, Japan, or other jurisdictions. Patent term, prosecution history, claim construction, and national validation differ by country.

What revenue exposure does AUSTEDO create?

Teva reported AUSTEDO as a major growth product, with approximately $1.2 billion in 2023 revenue.[9] The exposure is concentrated in:

• Continued use of AUSTEDO XR.
• Retention of patients transitioning from immediate-release AUSTEDO.
• Expansion in tardive dyskinesia.
• Huntington’s disease chorea demand.
• Reimbursement and specialty-pharmacy access.
• Timing of generic entry.
• Ability to defend formulation and use patents.

A generic launch would likely affect immediate-release tablets first if those products have fewer formulation barriers. AUSTEDO XR may retain a longer commercial runway if its release-control patents, regulatory exclusivity, or bioequivalence requirements delay substitution.

Key Takeaways

• AUSTEDO’s strongest excipient opportunities are alternate oral delivery systems, not commodity excipient replacement.
• AUSTEDO XR reduces the commercial value of another routine tablet reformulation but increases the value of sprinkle, liquid, ODT, and enteral-administration technologies.
• Controlled-release polymers, taste-masking systems, low-moisture excipients, and co-processed direct-compression materials are the most relevant functional excipient categories.
• A formulation patent is stronger when it claims dissolution, pharmacokinetics, stability, particle architecture, or manufacturing conditions.
• Generic-entry analysis must separate AUSTEDO immediate-release tablets from AUSTEDO XR.
• Teva’s revenue exposure is material, with AUSTEDO generating approximately $1.2 billion in 2023.
• A differentiated formulation supported by a clear ANDA or 505(b)(2) strategy offers the strongest commercial position.

FAQs About AUSTEDO Excipient and Formulation Opportunities

Can AUSTEDO be reformulated as an oral suspension?

Yes. A suspension could target patients with dysphagia or caregiver-administered dosing, but it would require validated dose uniformity, stability, taste masking, microbial control, and an appropriate regulatory pathway.

Is AUSTEDO XR suitable for an orally disintegrating tablet?

AUSTEDO XR is technically challenging for ODT development because rapid disintegration must coexist with controlled drug release. A multiparticulate system or coated-particle dosage form may be more practical than a conventional XR ODT.

Which excipient is most important for an AUSTEDO XR generic?

No single excipient determines bioequivalence. The critical formulation variables are the release-controlling matrix, tablet porosity, drug distribution, compression conditions, and dissolution profile.

Could a sprinkle formulation obtain separate patent protection?

Yes. A sprinkle formulation could support patents covering coated particles, release performance after administration with food, taste masking, particle-size distribution, or dose uniformity.

Would an AUSTEDO liquid automatically avoid Teva’s tablet patents?

Not necessarily. A liquid may avoid a narrow tablet-composition claim but could implicate active-ingredient, method-of-use, process, or broader formulation patents. Freedom to operate requires claim-by-claim analysis across the relevant jurisdictions.

References

1. U.S. Food and Drug Administration. (2024). AUSTEDO (deutetrabenazine) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). AUSTEDO XR (deutetrabenazine) extended-release tablets: Prescribing information.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Patent and Trademark Office. (2025). Patent Center and patent term adjustment records.
5. U.S. Food and Drug Administration. (2017, April 3). FDA approves first drug to treat chorea in Huntington’s disease.
6. U.S. Food and Drug Administration. (2017). AUSTEDO approval letter and approval history.
7. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
8. U.S. Food and Drug Administration. (2024). INGREZZA (valbenazine) capsules and tablets: Prescribing information.
9. Teva Pharmaceutical Industries Ltd. (2024). 2023 annual report.